Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-26 @ 12:31 AM
NCT ID:
NCT03696160
Group ID:
EG001
Title:
Symtuza
Description:
Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.
Symtuza® received marketing authorisation valid throughout the EU in September 2017.
Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)
Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food.
Deaths Number Affected:
3
Deaths Number At Risk:
None
Serious Number Affected:
54
Serious Number At Risk:
222
Other Number Affected:
120
Other Number At Risk:
222
Study:
NCT03696160
Results Section:
NCT03696160
Adverse Events Module:
NCT03696160